AB Science fournit le résumé de la conférence web avec les principaux leaders d’opinion autour des résultats de la phase 3 du masitinib dans l’asthme sévère
December 02, 2019 16:31 ET
|
AB Science
Paris, 2 décembre 2019, 22h15 Résumé de la conférence web avec les principaux leaders d’opinion autourdes résultats de la phase 3 du masitinib dans l’asthme sévère non contrôlé par les...
AB Science provides the summary of webcast with Key Opinion Leaders on masitinib Phase 3 results in severe asthma uncontrolled by oral corticosteroids
December 02, 2019 16:31 ET
|
AB Science
Paris, 02 December 2019, 10.15pm Summary of webcast with Key Opinion Leaders on masitinibPhase 3 results in severe asthma uncontrolled by oral corticosteroids AB Science SA (NYSE Euronext -...
Equillium to Host Business Update Call on October 1, 2019
September 17, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, leveraging deep understanding of immunobiology to develop products to treat...
Equillium to Present at H. C. Wainwright 21st Annual Global Investment Conference
August 27, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Announces Initiation of the EQUIP Phase 1b Clinical Trial of Itolizumab for Patients with Uncontrolled Asthma
July 10, 2019 08:07 ET
|
Equillium
LA JOLLA, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...
Equillium to Present at Jefferies 2019 Healthcare Conference
May 23, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., May 23, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Expands Scientific and Clinical Advisory Team
May 06, 2019 08:30 ET
|
Equillium
LA JOLLA, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium to Present at Solebury Trout Class of 2018 Biotech IPO Investor Day
April 16, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Bruce...
Equillium Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
March 27, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...
Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
February 26, 2019 16:07 ET
|
Equillium
Clinical trial evaluating EQ001 for the treatment of refractory lupus nephritis to commence in 2H 2019 Ongoing EQ001 development programs in acute graft-versus-host disease and severe asthma remain...